期刊文献+

抗肿瘤药物索拉非尼合成工艺的改进 被引量:2

Improved Synthesis of Antitumor Drug Sorafenib
暂未订购
导出
摘要 以2-吡啶甲酸(2)为起始原料,经氯化、酯化一锅法合成高纯度的中间体(4),中间体(4)经酰胺化得到中间体(5),(5)在TBAB和氢氧化钠存在下,与对氨基苯酚亲核取代成醚得到中间体(6);3-三氟甲基-4-氯苯胺(7)和三光气反应,经减压蒸馏纯化得到相应的异氰酸酯(8);(6)与4--氯-3-三氟甲基苯异氰酸酯(8)缩合制得索拉非尼(1).改进后的合成工艺总收率达69.7%,生产成本低,环境友好,操作简单且易于工业化生产. The intermediate methyl 4-ehloropicolinate (4) is prepared from picolinic acid (2) as a starting material by chloration and esterification. Its amidation afford 4-chloro-N-methylpicolinamide (5) which is converted into key intermediate 4-(4-aminophenoxy)-N-methylpicolinamide (6) by aromatic nucleophilic substitution with 4-amino- phenol. 4-chloro-3- (trifluoromethyl) phenyhsocyanate ( 8 ) is obtained from 4-chloro-3-trifluoromethylanihne ( 7 ) by isocyanation with triphosgene. The synthesis of title compound is completed by the condensation of intermediate (6) with (8). This process has the features of cheap material, simple operation, high yield and green chemistry.
机构地区 烟台大学药学院
出处 《烟台大学学报(自然科学与工程版)》 CAS 2012年第2期146-149,共4页 Journal of Yantai University(Natural Science and Engineering Edition)
关键词 索拉非尼 多激酶抑制剂 异氰酸酯 抗肿瘤药物 合成 sorafenib muti-kinase inhibitor isocyanate antitumor drug synthesis
  • 相关文献

参考文献9

  • 1周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 2Wilhelm S M,Carter C,Tang L. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Research,2004,(19):7099-7109.doi:10.1158/0008-5472.CAN-04-1443.
  • 3Rossetto P,Macdonald P L,Canavesi A. Process for the preparation of sorafenib and salts thereof[P].WO,2009111061,2009.
  • 4Bankston D,Dumas J,Natero R. A scaleable synthesis of BAY43-9006:A potent raf kinase inhibitor for the treatment of cancer[J].Organic Process Research & Development,2002,(06):777-781.doi:10.1021/op020205n.
  • 5Riedl B,Dumas J,Khire U. Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors[P].US,20030207872,2003.
  • 6Loegers M,Gehring R,Kuhn O. Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl) ph-enyl]amino} carbonyl) amino]phenoxy }-N-methylpyridine-2-carbox-amide[P].WO,2006034796,2006.
  • 7吴思晋,张晓蕾,沈义鹏,张爱华.索拉非尼的合成工艺改进[J].齐鲁药事,2008,27(3):168-170. 被引量:5
  • 8赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 9Pulla R,Muddasani,Venkaiah C. Process for the preparation of sorafenib[P].WO,2009054004,2009.

二级参考文献29

  • 1王绪根,谭心舜.异氰酸酯的反应动力学研究[J].青岛科技大学学报(自然科学版),2005,26(5):382-385. 被引量:6
  • 2钟敏.未来的重磅炸弹级药物[J].上海医药,2006,27(2):80-83. 被引量:3
  • 3吕允凤,封宇飞,胡欣,毕开顺.索拉非尼的药理及临床研究[J].中国新药杂志,2007,16(1):88-91. 被引量:17
  • 4车文军,李志裕,尤启冬.抗肿瘤药物新靶点与新药研究[J].药学进展,2007,31(6):247-253. 被引量:13
  • 5[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
  • 6[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
  • 7[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
  • 8[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
  • 9[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
  • 10[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144

共引文献70

同被引文献23

  • 1赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 2BANKSTON D ,DUMAS J ,NATERO R,et al. A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer [J]. Org. Proc. Res. Dev. , 2002,6(9) :777-781.
  • 3LOEGERS M, GEHRING R, KUHN O, eta|. Process for thepreparation of 4-14-[ ( I t 4-chloro-3-(trifluoromethyl) phenyl ~ amino I carbonyl ) amino ~ phenoxy } -N-methylpyri- dine-2-carboxamide : WO, 2 006 034 796[ P ]. 2006-04- 06.
  • 4RIEDL B,DUMAS J, KHIRE U, et al. Omega-carboxyar- ylsubstituted diphenyl ureas as raf kinase inhibitors: USA,2 001 011 135[P] .2001-08-02.
  • 5DUMAS J,SCOTT W J,ELTING J,et al. Aryl ureas with angiogenesis inhibiting activity:USA,2 003 207 870 [ P]. 2 003-11-06.
  • 6洛格斯AM,格林R,库恩O,等.制备4-{4-[({[(4-氯-3.三氟甲基-苯基)氨基]羰基}氨基]苯氧基}-N-甲基吡啶-2-甲酰胺的方法:中国,80037368[P].2007-10-10.
  • 7格鲁南伯格A,兰茨J.BAY43-9006甲苯磺酸盐的热力学稳定形式:中国,80040775[P].2007-10-31.
  • 8吴思晋,张晓蕾,沈义鹏,张爱华.索拉非尼的合成工艺改进[J].齐鲁药事,2008,27(3):168-170. 被引量:5
  • 9孙敏,魏红涛,蔡进,吉民.索拉非尼的合成[J].中国药学杂志,2009,44(5):394-396. 被引量:8
  • 10张庆文,周后元,尤启冬.一锅法制备抗肿瘤药对甲苯磺酸索拉非尼[J].中国药物化学杂志,2010,20(5):358-361. 被引量:8

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部